A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

NCT02031744 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

530

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: erlotinib [Tarceva]
DRUG: Placebo
DRUG: Onartuzumab [MetMAb]

Sponsor

Hoffmann-La Roche